Guadalupe Y Solís-Cruz, Rocío Alvarez-Roman, Verónica M Rivas-Galindo, Sergio Arturo Galindo-Rodríguez, David A Silva-Mares, Iván A Marino-Martínez, Magdalena Escobar-Saucedo, Luis A Pérez-López
{"title":"利奥扎特里酮聚合物纳米颗粒的配方和优化:一种具有潜在抗疱疹活性的纳米制剂。","authors":"Guadalupe Y Solís-Cruz, Rocío Alvarez-Roman, Verónica M Rivas-Galindo, Sergio Arturo Galindo-Rodríguez, David A Silva-Mares, Iván A Marino-Martínez, Magdalena Escobar-Saucedo, Luis A Pérez-López","doi":"10.2478/acph-2023-0028","DOIUrl":null,"url":null,"abstract":"<p><p>Riolozatrione (RZ) is a diterpenoid compound isolated from a dichloromethane extract of the <i>Jatropha dioica</i> root. This compound has been shown to possess moderate antiherpetic activity <i>in vitro</i>. However, because of the poor solubility of this compound in aqueous vehicles, generating a stable formulation for potential use in the treatment of infection is challenging. The aim of this work was to optimize and physio-chemically characterize Eudragit<sup>®</sup> L100-55-based polymeric nanoparticles (NPs) loaded with RZ (NPR) for <i>in vitro</i> antiherpetic application. The NPs formulation was initially optimized using the dichloromethane extract of <i>J. dioica</i>, the major component of which was RZ. The optimized NPR formulation was stable, with a size of 263 nm, polydispersity index < 0.2, the zeta potential of -37 mV, and RZ encapsulation efficiency of 89 %. The NPR showed sustained release of RZ for 48 h with release percentages of 95 and 97 % at neutral and slightly acidic pH, respectively. Regarding <i>in vitro</i> antiherpetic activity, the optimized NPR showed a selectivity index for HSV-1 of ≈16 and for HSV-2 of 13.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 3","pages":"457-473"},"PeriodicalIF":2.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Formulation and optimization of polymeric nanoparticles loaded with riolozatrione: a promising nanoformulation with potential antiherpetic activity.\",\"authors\":\"Guadalupe Y Solís-Cruz, Rocío Alvarez-Roman, Verónica M Rivas-Galindo, Sergio Arturo Galindo-Rodríguez, David A Silva-Mares, Iván A Marino-Martínez, Magdalena Escobar-Saucedo, Luis A Pérez-López\",\"doi\":\"10.2478/acph-2023-0028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Riolozatrione (RZ) is a diterpenoid compound isolated from a dichloromethane extract of the <i>Jatropha dioica</i> root. This compound has been shown to possess moderate antiherpetic activity <i>in vitro</i>. However, because of the poor solubility of this compound in aqueous vehicles, generating a stable formulation for potential use in the treatment of infection is challenging. The aim of this work was to optimize and physio-chemically characterize Eudragit<sup>®</sup> L100-55-based polymeric nanoparticles (NPs) loaded with RZ (NPR) for <i>in vitro</i> antiherpetic application. The NPs formulation was initially optimized using the dichloromethane extract of <i>J. dioica</i>, the major component of which was RZ. The optimized NPR formulation was stable, with a size of 263 nm, polydispersity index < 0.2, the zeta potential of -37 mV, and RZ encapsulation efficiency of 89 %. The NPR showed sustained release of RZ for 48 h with release percentages of 95 and 97 % at neutral and slightly acidic pH, respectively. Regarding <i>in vitro</i> antiherpetic activity, the optimized NPR showed a selectivity index for HSV-1 of ≈16 and for HSV-2 of 13.</p>\",\"PeriodicalId\":7034,\"journal\":{\"name\":\"Acta Pharmaceutica\",\"volume\":\"73 3\",\"pages\":\"457-473\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Pharmaceutica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/acph-2023-0028\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2023-0028","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Formulation and optimization of polymeric nanoparticles loaded with riolozatrione: a promising nanoformulation with potential antiherpetic activity.
Riolozatrione (RZ) is a diterpenoid compound isolated from a dichloromethane extract of the Jatropha dioica root. This compound has been shown to possess moderate antiherpetic activity in vitro. However, because of the poor solubility of this compound in aqueous vehicles, generating a stable formulation for potential use in the treatment of infection is challenging. The aim of this work was to optimize and physio-chemically characterize Eudragit® L100-55-based polymeric nanoparticles (NPs) loaded with RZ (NPR) for in vitro antiherpetic application. The NPs formulation was initially optimized using the dichloromethane extract of J. dioica, the major component of which was RZ. The optimized NPR formulation was stable, with a size of 263 nm, polydispersity index < 0.2, the zeta potential of -37 mV, and RZ encapsulation efficiency of 89 %. The NPR showed sustained release of RZ for 48 h with release percentages of 95 and 97 % at neutral and slightly acidic pH, respectively. Regarding in vitro antiherpetic activity, the optimized NPR showed a selectivity index for HSV-1 of ≈16 and for HSV-2 of 13.
期刊介绍:
AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.